FIG. 3.
INI-0602 decreased pro-inflammatory cytokine expression and increased brain-derived neurotrophic factor (BDNF) expression. INI-0602 treatment decreased tumor necrosis factor (TNF)-α and interleukin (IL)-1 at 1 and 2 weeks, but increased IL-6 and BDNF levels mostly at 1 week. *p<0.05. The values represent relative expression compared with non-treatment controls at each time point. GAPDH, glyceraldehyde-3-phosphate dehydrogenase.